Carmen Gil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4254743/publications.pdf

Version: 2024-02-01

123 papers	6,725 citations	101543 36 h-index	66911 78 g-index
139 all docs	139 docs citations	139 times ranked	8639 citing authors

#	Article	IF	Citations
1	Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry, 2022, 65, 935-954.	6.4	30
2	New insights into the role of endosomal proteins for African swine fever virus infection. PLoS Pathogens, 2022, 18, e1009784.	4.7	19
3	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	6.4	20
4	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. Biomedicines, 2022, 10, 1136.	3.2	4
5	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDPâ€43â€related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 2021, 156, 379-390.	3.9	20
6	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	5.4	28
7	Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses. Antiviral Research, 2021, 186, 104990.	4.1	23
8	Discovery of Amoebicidal Compounds by Combining Computational and Experimental Approaches. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	2
9	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 2021, 210, 112968.	5.5	26
10	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 2021, 186, 105011.	4.1	15
11	Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography. International Journal of Molecular Sciences, 2021, 22, 2440.	4.1	4
12	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 3206.	4.1	15
13	Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 1-3.	5.0	25
14	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	3.8	21
15	Small molecule inhibitors of mammalian GSK-3Î² promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. Journal of Experimental Botany, 2021, 72, 7808-7825.	4.8	4
16	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Research, 2021, 194, 105167.	4.1	19
17	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. European Journal of Medicinal Chemistry, 2021, 223, 113654.	5.5	10
18	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry, 2020, 63, 2638-2655.	6.4	10

#	Article	IF	Citations
19	Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 199-210.	5.2	12
20	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiology of Aging, 2020, 96, 148-154.	3.1	6
21	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	6.4	348
22	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449.	3.3	44
23	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 511-523.	5.2	2
24	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinsonâ€™s Disease Using Cheminformatics Approaches. Advances in Intelligent Systems and Computing, 2019, , 63-70.	0.6	3
25	Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. Future Medicinal Chemistry, 2019, 11, 1703-1720.	2.3	8
26	Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
27	Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 35-43.	3.4	10
28	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinsonâ€™s Disease. Journal of Integrative Bioinformatics, 2019, 16, .	1.5	11
29	Amyloid Î²-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer's Research and Therapy, 2018, 10, 24.	6.2	64
30	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 2018, 13, 19.	10.8	28
31	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. Journal of Medicinal Chemistry, 2018, 61, 5910-5921.	6.4	10
32	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
33	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E999-E1008.	7.1	40
34	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 522-526.	5.2	19
35	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. European Journal of Medicinal Chemistry, 2017, 130, 60-72.	5.5	21
36	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 403-414.	4.1	22

#	Article	IF	Citations
37	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	3.3	40
38	Inhibition of hippocampal long-term potentiation by high-fat diets. NeuroReport, 2017, 28, 354-359.	1.2	13
39	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinsonâ€™s disease. Future Medicinal Chemistry, 2017, 9, 731-748.	2.3	11
40	Subtly Modulating Glycogen Synthase Kinase 3 Î²: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	6.4	52
41	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 2017, 80, 27-36.	2.1	23
42	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	4.1	23
43	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1Î´ Inhibitors in Models of Parkinsonâ€™s Disease. ACS Omega, 2017, 2, 5215-5220.	3.5	10
44	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. Journal of Chemical Information and Modeling, 2017, 57, 2143-2151.	5.4	28
45	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. European Journal of Medicinal Chemistry, 2017, 138, 328-342.	5.5	24
46	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells, 2017, 35, 458-472.	3.2	36
47	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules, 2017, 22, 1472.	3.8	6
48	Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. RSC Drug Discovery Series, 2017, , 153-178.	0.3	2
49	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS ONE, 2016, 11, e0162723.	2.5	10
50	Targeting TDP-43 phosphorylation by Casein Kinase-1Î´ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 36.	10.8	55
51	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 2016, 116, 281-289.	5.5	10
52	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry, 2016, 16, 3527-3535.	2.1	16
53	<scp>PDE</scp>7 inhibitor <scp>TC</scp>3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 2015, 172, 4277-4290.	5.4	30
54	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 2015, 36, 1160-1173.	3.1	29

#	Article	IF	Citations
55	Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences, 2015, 4, 6-21.	3.9	2
56	Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. Stem Cells Translational Medicine, 2015, 4, 564-575.	3.3	38
57	Solid phase synthesis of functionalized indazoles using triazenes â€“ scope and limitations. RSC Advances, 2015, 5, 65540-65545.	3.6	6
58	Supercritical fluid extraction of grape seeds: extract chemical composition, antioxidant activity and inhibition of nitrite production in LPS-stimulated Raw 264.7 cells. Food and Function, 2015, 6, 2607-2613.	4.6	26
59	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. RSC Advances, 2015, 5, 15800-15811.	3.6	19
60	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2015, 22, 3789-3806.	2.4	21
61	Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2014, 57, 2755-2772.	6.4	95
62	Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8590-8607.	6.4	24
63	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents, 2014, 24, 1311-1321.	5.0	77
64	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 2014, 5, 194-204.	3.5	25
65	Glycogen Synthase Kinase-3Î² Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. British Journal of Medicine and Medical Research, 2014, 4, 263-271.	0.2	3
66	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	5.4	51
67	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	3.5	69
68	Methyl jasmonate treatment of strawberry fruits enhances antioxidant activity and the inhibition of nitrite production in LPS-stimulated Raw 264.7 cells. Journal of Functional Foods, 2013, 5, 1803-1809.	3.4	15
69	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. European Journal of Medicinal Chemistry, 2013, 70, 781-788.	5.5	5
70	Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2013, 170, 602-613.	5.4	48
71	Î²-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environmental Toxicology and Pharmacology, 2013, 36, 243-255.	4.0	60
72	Microwave-Assisted Solid-Phase Synthesis of a 1,2-Disubstituted Benzimidazole Library by Using a Phosphonium Linker. Journal of Heterocyclic Chemistry, 2013, 50, 720-726.	2.6	7

#	Article	IF	Citations
73	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2133-2145.	3.1	77
74	Dual inhibitor of PDE7 and GSK-3 â€“ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	4.1	56
75	Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinsonâ€™s Disease. RSC Drug Discovery Series, 2013, , 294-307.	0.3	5
76	Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease. Current Topics in Medicinal Chemistry, 2013, 13, 1808-1819.	2.1	31
77	Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 2012, 3, 793-803.	3.5	24
78	Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds. Journal of Medicinal Chemistry, 2012, 55, 3274-3284.	6.4	52
79	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 2012, 122, 1193-1202.	3.9	15
80	Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. European Journal of Medicinal Chemistry, 2012, 58, 44-49.	5.5	17
81	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	6.4	76
82	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	3.5	139
83	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. European Journal of Medicinal Chemistry, 2012, 47, 175-185.	5.5	64
84	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3Î² (GSK-3Î²) and phosphodiesterase 7 (PDE7) inhibitors: Determination of bloodâ€“brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 2012, 45, 677-684.	4.0	30
85	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	6.4	91
86	Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	2.0	69
87	Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE, 2011, 6, e17240.	2.5	83
88	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	6.4	84
89	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, 2011, 31, 924-954.	10.5	124
90	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	2.5	59

#	Article	IF	Citations
91	Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials. RSC Drug Discovery Series, 2010, , 173-194.	0.3	1
92	Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesteraseâ€...7 Inhibitors. ChemMedChem, 2009, 4, 866-876.	3.2	56
93	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. European Journal of Medicinal Chemistry, 2009, 44, 5055-5065.	5.5	33
94	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorganic and Medicinal Chemistry, 2009, 17, 6914-6925.	3.0	49
95	Solid-Phase Synthesis of Biologically Active Benzoannelated Nitrogen Heterocycles: An Update. ACS Combinatorial Science, 2009, 11, 175-197.	3.3	131
96	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 2008, 43, 1349-1359.	5.5	33
97	Non-ATP competitive glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 495-510.	3.0	57
98	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2008, 16, 6193-6206.	3.0	20
99	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Therapeutic Patents, 2008, 18, 1127-1139.	5.0	42
100	Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorganic and Medicinal Chemistry, 2006, 14, 1644-1652.	3.0	128
101	Organic Synthesis on Polymeric Supports. , 2005, , 137-199.		2
102	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1919-1921.	2.2	6
103	Organic Azides: An Exploding Diversity of a Unique Class of Compounds. Angewandte Chemie - International Edition, 2005, 44, 5188-5240.	13.8	1,894
104	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 2005, 25, 229-244.	10.5	111
105	Efficient Solid-Phase Synthesis of Highly Functionalized 1,4-Benzodiazepin-5-one Derivatives and Related Compounds by Intramolecular Aza-Wittig Reactions. Chemistry - A European Journal, 2005, 11, 2680-2688.	3.3	48
106	Traceless and Multifunctional Linkers for the Generation of Small Molecules on Solid Supports. ChemInform, 2005, 36, no.	0.0	0
107	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. ChemInform, 2005, 36, no.	0.0	0
108	Organic Azides: An Exploding Diversity of a Unique Class of Compounds. ChemInform, 2005, 36, no.	0.0	0

#	Article	IF	Citations
109	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. QSAR and Combinatorial Science, 2004, 23, 89-98.	1.4	34
110	Traceless and multifunctional linkers for the generation of small molecules on solid supports. Current Opinion in Chemical Biology, 2004, 8, 230-237.	6.1	48
111	The Synthesis of 3-Substituted 6-Aryl-3H-benzo[a][1,2,3]triazinones Using Polymer-Bound Triazenes. ACS Combinatorial Science, 2004, 6, 38-42.	3.3	34
112	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activityâ˜†. Bioorganic and Medicinal Chemistry, 2003, 11, 2395-2402.	3.0	5
113	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 107-114.	0.6	11
114	The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. Bioorganic and Medicinal Chemistry, 2002, 10, 2415-2437.	3.0	268
115	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	5.5	48
116	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	10.5	27
117	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.6	6
118	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:â€‰ First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	6.4	74
119	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	6.4	27
120	Nonnucleoside Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	6.4	27
121	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	2.2	10
122	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 1999, 55, 12405-12410.	1.9	12
123	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	6.4	26